key: cord-1054266-f4johm22
authors: Pérez-Torres, David; Díaz-Rodríguez, Cristina; Armentia-Medina, Alicia
title: Anti-ACTH Antibodies in Critically Ill Covid-19 Patients: A Potential Immune Evasion Mechanism of SARS-CoV-2
date: 2021-10-08
journal: Med Intensiva
DOI: 10.1016/j.medin.2021.09.002
sha: 11034ae1c95eecdf89befc1227cc873a37d668b2
doc_id: 1054266
cord_uid: f4johm22

nan

important intellectual content. All the authors approved the final version of the manuscript to be published.

Coronavirus disease 2019 (Covid-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in high morbimortality worldwide. SARS-CoV-2 exhibits a great number of mechanisms to evade the immune response, including suppression of the host's cortisol stress response 1 . Several potential mechanisms for adrenal insufficiency (AI) have been proposed 2 . One of them is based on the expression of amino acid sequences by SARS-CoV-2 that are remarkably similar to those of the host adrenocorticotropic hormone (ACTH) 1, 3 .

Production of antibodies against viral antigens may also lead to destruction of the host ACTH, avoiding the increase of cortisol and resulting in a relative AI. However, there is little data on the evidence of the existence of anti-ACTH antibodies and on the levels of cortisol in Covid-19 patients 1,3 .

We performed a proof-of-concept study to assess whether anti-ACTH antibodies were detectable in critically ill Covid-19 patients. We measured plasma levels of cortisol and ACTH as exploratory variables. The study was approved by the Institutional Ethics Review Board. Informed consent was obtained from the patient or representative prior to enrollment. We measured specific anti-ACTH IgE-class antibodies (ImmunoCAP™ IgE assays, Thermo Fisher Scientific/Phadia, Uppsala, Sweden), and plasma levels of cortisol and ACTH, at the moment when inclusion criteria were fulfilled (Table 1) . We found specific anti-ACTH IgE-class antibodies in 60% of Covid-19 patients with suspected AI, half of them together with low levels of plasma cortisol and ACTH. Note 70% of the patients were receiving corticosteroids at the time of assessment (Table 1, Electronic Supplementary Material). We did not find detectable titers of these antibodies in controls. patients supports the predominance of a Th2 polarization, which primarily activates a humoral response, via interleukins 4 and 6 5, 6, 7 . This response has been linked to a dysregulated cytokine release or "cytokine storm", and has been associated with poor prognosis 6 . The reason why we decided to measure specific IgE-class antibodies is that the Th2 pathway is involved in allergen-specific and related IgEbased events, since IL-4 induces production of these antibodies by B cells 5, 7 . We Our study has some limitations. First, we only included Covid-19 patients with suspected AI, since anti-ACTH antibodies were expected to reduce ACTH levels, leading to a decrease in cortisol. This aimed to maximize the probability to demonstrate the existence of anti-ACTH antibodies, but may reduce generalizability.

Second, although inclusion criteria required at least two signs or symptoms of AI that were not straightforwardly explained by alternative confounders, these signs remain to be highly unspecific. Inclusion of patients without suspected AI would allow to assess the prevalence of anti-ACTH antibodies more accurately. Third, we were unable to recruit a control group of non-Covid-19 critically ill patients, since ICU occupancy rate by Covid-19 patients was close to 100% during the study period. A matched control group would be desirable in the future. Fourth, although anti-ACTH IgE-class antibodies were detected, our study did not assess other immunoglobulin classes, which would merit further exploration. Fifth, exogenous administration of corticosteroids at the moment of inclusion limits the interpretation of ACTH and cortisol levels. Last, the inherent limitations of a proof-of-concept study, including single center design and small sample size.

To our knowledge, this is the first time that anti-ACTH antibodies have been described in severely ill Covid-19 patients. We suggest SARS-CoV-2 may take advantage of its homology with human ACTH to evade the host immune system by blocking the primary immune response and blunting the natural response of the hypothalamic-pituitary-adrenal axis to stress, leading to a relative AI state. We believe anti-ACTH antibodies play a plausible role in the pathophysiology of severe Covid-19, which may have potential clinical implications and merits further research. 

COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications

Adrenal insufficiency in the COVID-19 era

Hypocortisolism in survivors of severe acute respiratory syndrome (SARS)

Dexamethasone in Hospitalized Patients with Covid-19

IL-4/IL-13 remodeling pathway of COVID-19 lung injury

T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression

The expanding universe of T-cell subsets: Th1, Th2 and more